Peptide News Digest

#Microneedle

2 stories

Industry · View digest

Anodyne Nanotech Raises $12.6M Series A to Move a Needle-Free Once-Weekly GLP-1 Patch Into Phase 1

Anodyne Nanotech closed a $12.6 million Series A, led by Velocity Partners, to advance ANN-101, a once-weekly GLP-1 skin patch, into first-in-human trials. The Boston company's HeroPatch solid-state microneedle platform delivers multi-milligram doses of peptides without injections or cold storage, aiming to reach the drug exposures obesity treatment requires. The round adds to a wave of investment in alternatives to weekly GLP-1 injections.

Industry · View digest

PharmaTher Files Provisional Patent for Microneedle Patch Delivery of BPC-157, GHK-Cu, TB-500, and KPV

PharmaTher Holdings filed a U.S. provisional patent on April 13 for stabilized peptide compositions delivered via its PharmaPatch microneedle platform, covering formulations for BPC-157, GHK-Cu, TB-500, KPV, and multi-peptide combinations. The April 16 announcement positions PharmaTher to capture needle-free delivery share if the FDA's July PCAC meeting moves peptides back to Category 1. Three of the four compounds are on the July agenda.